# Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

> **NCT05740215** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 158 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** F520
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05740215
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-23
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-05-22
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740215, "Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05740215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*